PHP
RAPT

Parkman Healthcare Partners’s RAPT Therapeutics RAPT Stock Holding History

Parkman Healthcare Partners’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,046
Closed -$896K – 95
2021
Q1 		$896K Buy
5,046
+1,899
+60% +$313K 0.21% 78
2020
Q4 		$497K Sell
3,147
-604
-16% -$131K 0.13% 81
2020
Q3 		$966K Sell
3,751
-1,249
-25% -$277K 0.26% 71
2020
Q2 		$1.16M Buy
+5,000
New +$773K 0.33% 67

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Parkman Healthcare Partners's RAPT Position: Q2 2021 in Review

Parkman Healthcare Partners sold out of RAPT Therapeutics (RAPT) in Q2 2021, closing a stake of 5,046 shares — an estimated $896K sold.

Parkman Healthcare Partners first reported a position in RAPT in Q2 2020 and held it in 4 quarters. The position peaked at $1.16M in Q2 2020. 109 funds tracked by Wall St. Rank hold RAPT as of Q2 2021.

  • Parkman Healthcare Partners reported no remaining RAPT Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 5,046 RAPT Therapeutics shares in Q2 2021, an estimated $896K.
  • Parkman Healthcare Partners first reported a position in RAPT Therapeutics in Q2 2020 and held it in 4 quarters.
  • Parkman Healthcare Partners's RAPT Therapeutics position peaked at $1.16M in Q2 2020.
  • 109 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2021.

Based on Parkman Healthcare Partners's 13F filing for Q2 2021, filed 13 Aug 2021.